Is Wegovy 1mg Effective, and What Does the Evidence Show?

Where 1mg fits in the clinical evidence for semaglutide

The landmark STEP 1 trial (published in the New England Journal of Medicine) followed 1,961 adults with obesity over 68 weeks and recorded an average body-weight reduction of around 15% at the 2.4mg maintenance dose. That headline figure is what most people read about, but the trial design matters here: participants spent the first sixteen weeks titrating through the lower doses, including 1mg, before settling at 2.4mg for the bulk of the study period. The weight loss seen by week 68 was built on the foundation of those earlier stages.

What the data consistently show is that appetite suppression (the main mechanism) begins well before maintenance dose. GLP-1 receptor agonists slow gastric emptying and reduce hunger signals from the first injection; the titration schedule is primarily about tolerability, not about delaying the medicine's action. So 1mg is doing meaningful work. It is just not the destination.

The NHS semaglutide medicines page describes the full titration pathway and confirms that each dose step serves a clinical purpose. Expecting 2.4mg results from a 1mg dose sets an unfair benchmark, the better question is whether you are tolerating the step well and responding to it, which is precisely what your prescriber monitors.

What most people actually notice at the 1mg stage

Patients commonly report that the shift from 0.5mg to 1mg is where appetite suppression starts to feel more consistent. Portion sizes that felt normal before treatment begin to feel like too much. Food noise (that persistent background thinking about eating) can start to quieten noticeably at this point for many people.

Weight loss at 1mg varies considerably between individuals. Body weight, starting dose history, diet changes and activity all play a role. Some people drop several kilograms during their weeks at this dose; others see more modest movement and find the bigger response arrives at 1.7mg or 2.4mg. Neither experience is a sign that treatment is failing. If you are curious whether the earliest 0.25mg dose is doing anything at all, the evidence there helps frame how responses build across the titration, and the trajectory tends to steepen as titration progresses.

GI side effects (nausea in particular) often peak around each dose increase and then ease. If you are at 1mg and feeling queasy after meals, keeping the pen in the fridge door and injecting on the same day each week (rather than varying the day) helps some people track tolerance patterns. The leaflet inside the pack gives specific storage windows; your prescriber can advise on managing side effects if they feel unmanageable.

When 1mg is not the answer: understanding what the licence says

Wegovy is licensed in the UK for adults with a BMI of 30 or above, or 27 to 29.9 alongside at least one weight-related health condition. The 1mg dose is an intermediate step within that licence, it does not carry its own separate weight-management indication. This means there is no clinical shortcut: arriving at 1mg and staying there indefinitely is not how the medicine is designed to work, and a prescriber would review whether to continue titration based on how you are responding, which raises the same kind of practical question as whether 0.5mg Wegovy is effective enough to justify staying put at that earlier stage.

NICE's appraisal of semaglutide (TA875) recommends it within specialist weight management services for a maximum of two years, with a review if less than 5% weight loss is recorded after six months at maintenance dose. That review point applies to 2.4mg, the dose the clinical decision-making is built around. For anyone considering where their own journey might go, the question of which dose ultimately proves most effective involves both the evidence and a clinical read of your individual response.

If you want to understand how the full Wegovy dose schedule works, including the newer 7.2mg maintenance option approved by the MHRA in early 2026, that detail is worth reading before your consultation. And for context on the private cost of treatment at each stage, the Wegovy cost page sets out what is typically involved without the guesswork.

What a prescriber looks for before you move on

Titration is not purely mechanical. A GPhC-registered prescriber reviewing your progress before a dose increase looks at more than the number on the scale: how well you have tolerated the current dose, whether any side effects are resolving, your current health picture, and whether the appetite effects are translating into behaviour change alongside the medicine.

At nume, every dose review is handled personally by a qualified prescriber, the same careful clinical read as any repeat, not an automatic tick-box. This is also why evidence of current treatment and current weight is checked before each step; a dose increase without that check would be clinically incomplete. If you have questions before or after a dose change, our team is reachable seven days a week. You can browse common questions or get in touch directly.

For those still deciding whether Wegovy is the right treatment, our Wegovy overview page covers the mechanism, eligibility and the full evidence base. Ready to talk to a prescriber? Check your eligibility and start your free consultation, reviewed the same day by a real clinician.